Jafron Biomedical Valuation Multiples

Jafron Biomedical Overview

About Jafron Biomedical

Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.

Founded

1989

HQ

Employees

N/A

Website

jafron.com

Sectors

BiopharmaceuticalsMedical DevicesBioTechDeepTechHealthTech

Financials (LTM)

Revenue: $323M

EBITDA: $124M

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Jafron Biomedical Financials

Jafron Biomedical reported last 12-month revenue of $323M and EBITDA of $124M.

In the same LTM period, Jafron Biomedical generated $257M in gross profit, $124M in EBITDA, and $83M in net income.

Jafron Biomedical P&L

In the most recent fiscal year, Jafron Biomedical reported revenue of $393M and EBITDA of $176M.

Jafron Biomedical expects next 12-month revenue of XXX and NTM EBITDA of XXX

Jafron Biomedical Stock Performance

Jafron Biomedical has current market cap of $2B, and enterprise value of $2B.

Jafron Biomedical's stock price is $2.57.

Jafron Biomedical Valuation Multiples

Jafron Biomedical trades at 5.9x EV/Revenue multiple, and 15.4x EV/EBITDA.

Jafron Biomedical Financial Valuation Multiples

As of April 19, 2026, Jafron Biomedical has market cap of $2B and EV of $2B.

Equity research analysts estimate Jafron Biomedical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Jafron Biomedical has a P/E ratio of 24.7x.

Jafron Biomedical Margins & Growth Rates

Jafron Biomedical's revenue in the last 12 month grew by 7%.

Jafron Biomedical's rule of 40 is 46% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Jafron Biomedical's rule of X is 57% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Jafron Biomedical Public Comps

See public comps and valuation multiples for other Biopharmaceuticals and Medical Devices comps.

Jafron Biomedical M&A Activity

Jafron Biomedical acquired XXX companies to date.

Last acquisition by Jafron Biomedical was on XXXXXXXX, XXXXX. Jafron Biomedical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Jafron Biomedical Investment Activity

Jafron Biomedical invested in XXX companies to date.

Jafron Biomedical made its latest investment on XXXXXXXX, XXXXX. Jafron Biomedical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).